熱門資訊> 正文
默克收购维罗纳制药公司获得法院批准
2025-10-07 04:46
- Merck's (NYSE:MRK) ~$10B acquisition of Verona Pharma (NASDAQ:VRNA) has been granted approval by the High Court of Justice of England and Wales.
- Under terms, MSD, the trade name of Merck outside the US and Canada, will acquire Verona Pharma for $107 per American Depository Share, with each one accounting for eight Verona ordinary shares.
- The deal closing is effective Oct. 7. Verona shares will no longer be traded as of market close Monday.
More on Merck
- Merck: A Race Against The Keytruda Clock
- Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors
- Merck: Game-Changing Oncology Drugs Power Stock Surge
- HHS ramps up drug pricing efforts with another proposed rule sent for review
- Trump holding off on pharma tariffs to negotiate more deals - report
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。